Cargando…

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review

Background: Schizophrenia negative symptoms (SNS) contribute substantially to poor functional outcomes, loss in productivity and poor quality of life. It is unclear which instruments may be used for assessing quality of life in patients with SNS. Objective: The objective of this review was to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azaiez, Chiraz, Millier, Aurélie, Lançon, Christophe, Clay, Emilie, Auquier, Pascal, Llorca, Pierre-Michel, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161588/ https://www.ncbi.nlm.nih.gov/pubmed/30275939 http://dx.doi.org/10.1080/20016689.2018.1517573

Ejemplares similares

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
por: Jarosławski, Szymon, et al.
Publicado: (2016)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
por: Thokagevistk, Katia, et al.
Publicado: (2016)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting
por: François, Clément, et al.
Publicado: (2017)

Toward Meeting the Needs of Homeless People with Schizophrenia: The Validity of Quality of Life Measurement
por: Auquier, Pascal, et al.
Publicado: (2013)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram
por: Llorca, Pierre-Michel, et al.
Publicado: (2015)

Microbiota-Orientated Treatments for Major Depression and Schizophrenia
por: Fond, Guillaume B., et al.
Publicado: (2020)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
por: Fond, Guillaume, et al.
Publicado: (2021)

Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study
por: Fond, Guillaume, et al.
Publicado: (2020)

Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
por: Hanna, Eve, et al.
Publicado: (2016)

Gene therapies development: slow progress and promising prospect
por: Hanna, Eve, et al.
Publicado: (2017)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study
por: FABRE, Cyprien, et al.
Publicado: (2021)

The Role of Inflammation in the Treatment of Schizophrenia
por: Fond, Guillaume, et al.
Publicado: (2020)

Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data
por: Rahhali, Nora, et al.
Publicado: (2015)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review
por: Fond, Guillaume, et al.
Publicado: (2018)

Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia
por: Michel, Pierre, et al.
Publicado: (2013)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Quality of life among caregivers of patients with schizophrenia: a cross-cultural comparison of Chilean and French families
por: Boyer, Laurent, et al.
Publicado: (2012)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

End of life breast cancer care in women with severe mental illnesses
por: Fond, Guillaume, et al.
Publicado: (2021)

Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
por: Clay, Emilie, et al.
Publicado: (2012)

The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D
por: Dorey, Julie, et al.
Publicado: (2016)

The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
por: Lançon, Christophe, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_dcf6vjvjfhvvu1cepih3pj69ct